Adage Capital Management, L.P., along with managing members Robert Atchinson and Phillip Gross, filed Amendment No. 2 to Schedule 13G with the SEC on November 12, 2026, disclosing a 2.26% beneficial ownership position in Tenax Therapeutics, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each of the three reporting persons - Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross - reported 857,270 shares beneficially owned.
  • Ownership percentage: The 857,270 shares represent 2.26% of Tenax Therapeutics common stock, based on 37,423,917 shares outstanding as of July 28, 2026.
  • Warrant component: The filing states that the aggregate figure includes 447,537 shares of common stock issuable upon exercise of warrants directly held by Adage Capital Partners, L.P.
  • Voting and dispositive power: All three reporting persons report 0 shares with sole voting or dispositive power, and 857,270 shares with shared voting and shared dispositive power.
  • Triggering event date: The date of the event requiring this filing is September 30, 2026.
  • Filing classification: Adage Capital Management, L.P. is classified as an investment adviser and limited partnership (IA, PN); Robert Atchinson and Phillip Gross are each classified as holding company and individual (HC, IN).

Adage Capital Management's Schedule 13G Amendment for Tenax Therapeutics

According to the filing, Adage Capital Management, L.P. (ACM), a Delaware limited partnership, serves as the investment manager of Adage Capital Partners, L.P. (ACP), which directly holds the common stock and warrants reported in this statement. The filing identifies ACM as the entity with investment management authority over the securities, while Robert Atchinson and Phillip Gross are disclosed as managing members of several affiliated entities that together form the general partner structure of ACM and ACP.

The filing reports that all 857,270 shares are held on a shared basis - no reporting person claims sole voting or sole dispositive power over any shares. The 857,270-share total includes 447,537 shares of common stock issuable upon exercise of warrants, as noted in the comment fields of each cover page. The percentage of class, 2.26%, is calculated using 37,423,917 shares of common stock outstanding as of July 28, 2026, as reported in Tenax Therapeutics' Form 10-Q for the quarterly period ended June 30, 2026, and assumes exercise of the warrants held by ACP.

The filing further states, under Item 5, that the reporting persons' ownership represents 5 percent or less of the class. The business address for all reporting persons is listed as 200 Clarendon Street, 52nd Floor, Boston, Massachusetts 02116. The filing notes: "The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein." Tenax Therapeutics is listed on NASDAQ:TENX and is incorporated in Delaware, with principal offices in Chapel Hill, NC.

What Was Disclosed

Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross filed Amendment No. 2 to Schedule 13G disclosing aggregate beneficial ownership of 857,270 shares, or 2.26%, of Tenax Therapeutics common stock as of September 30, 2026, including 447,537 warrant-linked shares.